Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488279 · ClinicalTrials.gov registry record · NA
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
A NA study, sponsored by University of Vermont.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT01488279 is a NA study that has completed, run by University of Vermont. The registered enrollment target is 10 participants.
The verdict
NCT01488279, a NA study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.
Interventions
- DRUG Dexamethasone 2.5 mg and Sitagliptin 100 mg
- DRUG Dexamethasone 2.5 mg and placebo tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-09 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01488279
The ClinicalTrials.gov registry entry for NCT01488279 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone 2.5 mg and Sitagliptin 100 mg is the first listed.
NCT01488279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01488279 about?
NCT01488279 is a clinical study titled "Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy". The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.
What is the current status of trial NCT01488279?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2012-09. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01488279?
The interventions under investigation include: Dexamethasone 2.5 mg and Sitagliptin 100 mg (DRUG), Dexamethasone 2.5 mg and placebo tablet (DRUG).
Who is sponsoring clinical trial NCT01488279?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.